Connecting with Patients, Overcoming Uncertainty The industry’s first white paper that provides strategies to help drug firms harness social media without violating DTC promotion regulations
Social media sites are rich with valuable conversations on health conditions, treatment experiences, and emotional support. However, the FDA has yet to issue guidance on how to conduct monitoring and marketing practices in social media so pharmaceutical companies are unsure how to proceed. The white paper and webinar provides a framework that will help drug firms discuss, evaluate, and minimize potential compliance risks in social media monitoring and marketing.
Panelists will provide specific guidance on the use of social media around these DTC principles:
1. Fair Balance: Ensuring the public receives information about a drug’s safety and efficacy 2. Off-Label Promotion: Marketing a product for a non-FDA approved condition 3. Adverse Event Reporting: Looking for and reporting information that may suggest a link between the use of a product and an adverse event or side effect
Please fill out the form below to download the white paper and listen to a recording of the webinar.
(Bold indicates required fields)
Your Name
Email Address
Title
Company Name
City, State
Primary Industry Choose One Automotive Consulting Consumer Products Financial Services Healthcare Insurance Media & Entertainment Non-profit Pharmaceutical Retail Technology Telecommunications Other
Interest Choose One Gathering Information Exploring Solutions Comparing Vendors Other
How did you hear about us? Choose One Search Engine Conference Article Press Release Referred Cymfony Website Cymfony Blog Direct e-mail Other
Business Phone
Send me email news of future white papers, upcoming events, and TNS MI/Cymfony updates
